泼尼松用于反复种植失败患者:双盲多中心随机安慰剂对照试验方案
本试验为前瞻性、多中心、随机、双盲、安慰剂对照临床研究,按1:1比例将反复种植失败(RIF)且拟行冻融胚胎移植(FET)的患者随机分为泼尼松组与安慰剂组,主要结局为活产率。研究旨在为泼尼松改善RIF患者妊娠结局提供随机对照证据。
要点
- 泼尼松从子宫内膜准备开始用至妊娠早期结束(若妊娠)。
- 主要结局为活产率,设计为1:1随机双盲安慰剂对照。
- 纳入拟行FET的RIF患者,涵盖IVF/ICSI/PGT-A后周期。
核心结论
- 本研究结果将为泼尼松对RIF患者妊娠结局的作用提供证据。
研究设计与样本
- 前瞻性、多中心、随机、双盲、安慰剂对照临床试验,泼尼松与安慰剂按1:1比例分组。
- 纳入拟行冻融胚胎移植的RIF不孕患者,涵盖IVF、ICSI或PGT-A后周期。
关键数值与推荐
- 主要结局为活产率。
- 干预从子宫内膜准备开始,若妊娠则持续至妊娠早期结束。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recurrent implantation failure (RIF) brings great challenges to clinicians and causes deep frustration to patients. Previous data has suggested that prednisone may play a promising role in the establishment of pregnancy and help improve the pregnancy outcome in women with RIF. But there is insufficient evidence from randomized clinical trials that had adequate power to determine if prednisone can enhance live births as the primary outcome. METHODS/DESIGN: This trial is a prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial (1:1 ratio of prednisone versus placebo). Infertile patients with RIF who intend to undergo frozen-thawed embryo transfer (FET) after in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) or pre-implantation genetic testing for aneuploidy (PGT-A) will be enrolled and randomly assigned to two parallel groups. Participants will be given the treatment of prednisone or placebo from the start of endometrial preparation till the end of the first trimester of pregnancy if pregnant. The primary outcome is live birth rate. DISCUSSION: The results of this study will provide evidence for the effect of prednisone on pregnancy outcomes in patients with RIF. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR1800018783 . Registered on 9 October 2018.
引用
- Lu Y, Yan J, Liu J, et al. Prednisone for patients with recurrent implantation failure: study protocol for a double-blind, multicenter, randomized, placebo-controlled trial. Trials. 2020. PMID: 32807234. doi:10.1186/s13063-020-04630-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。